Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

19-144

Sigma-Aldrich

Phorbol 12-Myristate 13-Acetate

≥99% (HPLC), solid, PKC activator, Upstate®

Sinónimos:

12-O-Tetradecanoylphorbol 13-acetate, 4β,9α,12β,13α,20-Pentahydroxytiglia-1,6-dien-3-one 12-tetradecanoate 13-acetate, PMA, TPA

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Código UNSPSC:
12352211
eCl@ss:
32160405
NACRES:
NA.41

Nombre del producto

Phorbol 12-Myristate 13-Acetate,

Formulario

solid

Nivel de calidad

100

fabricante / nombre comercial

Upstate®

técnicas

activity assay: suitable (kinase)

Condiciones de envío

wet ice

Descripción general

Phorbol 12-Myristate 13-Acetate (PMA) is obtained from the unripe fruit of Sapium indicum. It is a pro-inflammatory agent. PMA shows its effects by the release of cytokines, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, and proteases that result in tissue damage or activates histamine production. This promotes vascular remodeling, heat, and redness. PMA exhibits antimicrobial, proliferative, antiproliferative, anti-neoplastic effects.

Aplicación

Phorbol 12-Myristate 13-Acetate is suitable as an inducer of cell differentiation in monocytic cell lines such as U937 and THP-1.

Acciones bioquímicas o fisiológicas

Phorbol 12-Myristate 13-Acetate is a tumor-promoting phorbol ester. It regulates various processes such as gene transcription, cellular growth and differentiation, apoptosis, the immune response, and receptor desensitization via activating protein kinase C (PKC) signaling pathways. It promotes differentiation of human monocytic THP-1 cells to functional macrophages.

Forma física

C36H56O8

Almacenamiento y estabilidad

2 years at -20°C

Información legal

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Carc. 2 - Eye Dam. 1 - Resp. Sens. 1 - Skin Corr. 1B - Skin Sens. 1

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Agnes Schröder et al.
Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie (2022-04-22)
Orthodontic tooth movement is a complex process involving the remodeling of extracellular matrix and bone as well as inflammatory processes. During orthodontic treatment, sterile inflammation and mechanical loading favor the production of receptor activator of NF-κB ligand (RANKL). Simultaneously, expression of
12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs.
Han, Z T, et al.
Proceedings of the National Academy of Sciences of the USA, 95, 5362-5365 (1998)
Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-kappaB, but not p38 MAPK, pathways.
Chang, et al.
Cellular Signalling, 17, 299-310 (2018)
In vitro studies on the mode of action of the phorbol esters, potent tumor promoters: part 1.
Blumberg, P M
Critical Reviews in Toxicology, 8, 153-197 (1980)
Gabriele Picco et al.
Cancer discovery, 11(8), 1923-1937 (2021-04-11)
Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer. The clinical effectiveness of targeted therapy and chemotherapy is limited by resistance and drug toxicities, and about half of patients receiving immunotherapy
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico